Abstract
Phenothiazines and butyrophenones are known to alter dopamine (3,4-dihydroxyphenethylamine) metabolism in the brain in a fashion suggesting that they may block dopamine receptors. We observed, using Dreiding molecular models, that dopamine in its solid-state conformation is superimposable upon a portion of the known x-ray structure of chlorpromazine [2-chloro-10-(3-dimethylaminopropyl)-phenothiazine]. The ability of phenothiazine drugs to mimic the dopamine-like conformation correlates with their antischizophrenic efficacy. These structure-activity relationships explain the importance of a substituent in ring a, a three-carbon side chain bearing the amino group, and a hetero atom between rings a and c.
Keywords: x-ray structure, neuroleptic activity, cis and trans isomers
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andén N. E., Butcher S. G., Corrodi H., Fuxe K., Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970;11(3):303–314. doi: 10.1016/0014-2999(70)90006-3. [DOI] [PubMed] [Google Scholar]
- Brotzu G. Inhibition by chlorpromazine of the effects of dopamine on the dog kidney. J Pharm Pharmacol. 1970 Sep;22(9):664–667. doi: 10.1111/j.2042-7158.1970.tb12750.x. [DOI] [PubMed] [Google Scholar]
- Carlström D., Bergin R. The structure of the catecholamines. I. The crystal structure of noradrenaline hydrochloride. Acta Crystallogr. 1967 Aug 10;23(2):313–319. doi: 10.1107/s0365110x67002646. [DOI] [PubMed] [Google Scholar]
- Davis J. M. Efficacy of tranquilizing and antidepressant drugs. Arch Gen Psychiatry. 1965 Dec;13(6):552–572. doi: 10.1001/archpsyc.1965.01730060070010. [DOI] [PubMed] [Google Scholar]
- GROGAN C. H., GESCHICKTER C. F., FREED M. E., RICE L. M. SPIRANES. VII. NEUROLEPTICS DERIVED FROM AZASPIRANES. J Med Chem. 1965 Jan;8:62–73. doi: 10.1021/jm00325a015. [DOI] [PubMed] [Google Scholar]
- Green A. L. Activity correlations and the mode of action of aminoalkylphenothiazine tranquillizers. J Pharm Pharmacol. 1967 Mar;19(3):207–208. doi: 10.1111/j.2042-7158.1967.tb08072.x. [DOI] [PubMed] [Google Scholar]
- JANSSEN P. A., NIEMEGEERS C. J., SCHELLEKENS K. H. IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS. Arzneimittelforschung. 1965 Feb;15:104–117. [PubMed] [Google Scholar]
- Janssen P. A., Niemegeers C. J., Schellekens K. H., Lenaerts F. M. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats. Arzneimittelforschung. 1967 Jul;17(7):841–854. [PubMed] [Google Scholar]
- Kier L. B., Truitt E. B., Jr The preferred conformation of dopamine from molecular orbital theory. J Pharmacol Exp Ther. 1970 Jul;174(1):94–98. [PubMed] [Google Scholar]
- Nybäck H., Sedvall G. Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J Pharmacol Exp Ther. 1968 Aug;162(2):294–301. [PubMed] [Google Scholar]
- Yeh B. K., McNay J. L., Goldberg L. I. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther. 1969 Aug;168(2):303–309. [PubMed] [Google Scholar]